Transient cortical blindness following vincristine therapy.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D019575:Blindness, Cortical / Q000139:chemically induced* / Q000503:physiopathology; D017024:Chemotherapy, Adjuvant; D002648:Child; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D007813:Laparotomy / Q000379:methods; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D018570:Risk Assessment; D014057:Tomography, X-Ray Computed; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D014750:Vincristine